E-Learning Center
Join Our Network

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906



5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

November 5-7, 2009

New York, New York

New York Marriott at The Brooklyn Bridge

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 17.75 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational Congress is specifically designed for hematologists, internists,oncologists and other physicians, physicians-intraining, and healthcare professionals (nurses, pharmacists) interested in and/or involved in the care of patients with myeloproliferative diseases and myelodysplastic syndromes.


After completion of this educational activity,participants should be able to:

  • Review the classification and pathogenesis of myelodysplastic diseases
  • Discuss current best practices in the treatment of MDS
  • Comment on novel drugs in MDS,with a focus on management of iron overload
  • Review new prognosticclassifications and their relevance to allogeneic transplantation in primary myelofibrosis
  • Discuss novel markers and therapies beyond JAK2 in myelofibrosis
  • Review important genetic abnormalities in myeloproliferative disorders
  • Comment on the clinical significance of mutations in polycythemia vera
  • Identify the importance of cerebral circulation in outcomes related to polycythemia vera
  • Discuss molecular drug targets in myeloproliferative disorders
  • Review risk factors for thrombosis in MPDs
  • Review the most current updates in the biology and pathogenesis of CML
  • Improve response monitoring and overcome drug resistance to improve CML outcomes
  • Review the management of CML in pregnancy
  • Discuss second and third generation tyrosine kinase inhibitors and their existing and future positioning within the current treatment armamentarium
  • Review treatment of accelerated and blast phase CML disease
  • Debate the optimal role of transplantation in CML

Tiziano Barbui, MD
Ospedali Riuniti di Bergamo
Bergamo, Italy

Giovanni Barosi, MD
IRCCS Policlinico San Matteo
Pavia, Italy

John M. Bennett, MD
University of Rochester
Medical Center
Rochester, New York

Francisco Cervantes, MD
Hospital Clinic, University
of Barcelona
Barcelona, Spain

Richard E. Champlin, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Stefan Constantinescu, MD, PhD
Ludwig Institute for Cancer Research
Brussels, Belgium

Jorges Cortes, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Nick C.P. Cross, MA, PhD, FRCPath
University of Southampton
Salisbury, United Kingdom

Heinz Gisslinger, MD
Medical University of Vienna
Vienna, Austria

John Goldman, MD
Hammersmith Hospital
Imperial College London
London, United Kingdom

Anthony R. Green, PhD, FRCP, FRCPath
Cambridge Institute for Medical Research
Addenbrooke’s Hospital
Cambridge, United Kingdom

Rudiger Hehlmann, MD, PhD
Klinikum Mannheim der Universität
Heidelberg Mannheim
Mannheim, Germany

Ronald Hoffman, MD
Mount Sinai School of Medicine
New York, New York

Hagop M. Kantarjian, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Jean-Jacques Kiladjian, MD, PhD
Hopital Avicenne and Paris 13 University
Bobigny, France

Alan F. List, MD
H. Lee Moffitt Cancer Center
and Research Institute
Tampa, Florida

Ruben A. Mesa, MD
Mayo Clinic
Rochester, Minnesota

Vesna Najfeld, MD
Mount Sinai School of Medicine
New York, New York

Heike L. Pahl, PhD
University Hospital Freiburg
Freiburg, Germany

Josef T. Prchal, MD
University of Utah
Health Sciences Center
Salt Lake City, Utah

Jerry Radich, MD
Fred Hutchinson Cancer
Research Center
Seattle, Washington

Gail J. Roboz, MD
Weill Cornell Medical College
New York, New York

Damiano Rondelli, MD
University of Illinois at Chicago
Chicago, Illinois

Andrew I. Schafer, MD
Weill Cornell Medical College
New York, New York

Christopher B. Schaffer, PhD
Cornell University
New York, New York

Richard T. Silver, MD, FACP
Weill Cornell Medical College
New York, New York

Radek Skoda, MD
University Hospital Basel
Basel, Switzerland

Jerry L. Spivak, MD, FACP
Johns Hopkins University
Balimore, Maryland

Ayalew Tefferi, MD
Mayo Clinic
Rochester, Minnesota

William Vainchenker, MD, PhD
Institut Gustave Roussy
Villejuif, France

Irving Weissman, MD
Stanford School of Medicine
Stanford, California

Neal S. Young, MD
National Institutes of Health
Bethesda, Maryland

sumbit abstracts now


Participants interested in presenting data should submit abstracts online at www.imedex.com by August 18, 2009. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final course book and scheduled for oral or poster presentation.

Acceptance notifications and guidelines for poster presentations will be sent by September 15, 2009. Authors of accepted abstracts who have not registered will have until October 22, 2009 to do so at the rate of $325. After this date, abstracts without registered presenters will be disregarded.

Abstract Guidelines

  • Follow the online instructions
  • Abstracts must be written in English
  • Accepted format: Word document format, 9 point Arial font,500 word count limit
  • Use a concise title
  • List affiliations of author(s) as briefl y as possible, with city, state and country
  • Place an asterisk (*) before the name of the presenting author
  • Use standard and well-accepted abbreviations
  • When using references, use standard and well-accepted formats
  • Abstract content should be single-spaced, typed in lower case and contain:
    • Purpose of the study
    • Summarized description of the project
    • Results and conclusions

Submission Deadline:
August 18, 2009

Submission Instructions:
Go to www.imedex.com, select this Congress and follow instructions in the "Abstracts" section.


Registration Fees

Discounted .....................................................$ 325
If payment received by September 1, 2009

Regular ..........................................................$ 425
If payment received by October 29, 2009

Full/Onsite ....................................................$ 525
If payment received after October 29, 2009

Group discount (physicians only)* ...............-$ 50
*cannot be combined with any other discounts

Nurses/Residents/Students* ..........................$ 199
*proof of eligibility must accompany registration *cannot be combined with any other discounts


To Register: You may register online by October 29,2009 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available to Nurses/Residents/Students.

Payment: To pre-register, registration and payment must be received no later than October 29, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than October 29, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 29, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

New York Marriott at the Brooklyn Bridge
333 Adams Street Brooklyn, New York 11201,
USA Tel.: +1 (718) 246 7000
Fax: +1 (718) 246 0563

Located in New York City’s most celebrated neighborhood, just across the river from Manhattan sits the New York Marriott at the Brooklyn Bridge. Fresh from a 2007 expansion and renovation, the hotel boasts a relaxed but modern atmosphere with state-of-the-art amenities. The hotel sits within Renaissance Plaza, adjacent to the Metro Tech Center and surrounding universities and is a short 5 minutes from Manhattan and the Financial District, with 9 major subway lines all within one block.

For the convenience of attendees, a limited number of rooms have been reserved until October 14, 2009 at a discounted rate of $ 299 single/double occupancy, plus tax New York State tax (8.375%), New York City tax (5%) and occupancy tax ($3.50) per night. This rate is not guaranteed outside the congress dates or after October 14, 2009.

To reserve your room please contact New York Marriott at the Brooklyn Bridge reservations department at (888) 436 3759 or (718) 246 7000. To receive the group rate, callers must identify themselves as being with the International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. Reservation requests received after October 14, 2009 may not be guaranteed the group rate.

Chair and Convener:
Richard T. Silver, MD, FACP
Weill Cornell Medical College
New York, New York

Jerry L. Spivak, MD, FACP
Johns Hopkins University
Baltimore, Maryland


Dear Colleague,
It is our pleasure to invite you to join us at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. The 2009 Congress, which will be held November 5-7 at the New York Marriott at the Brooklyn Bridge, promises to be our most exciting and interactive meeting yet!

Since the inaugural Congress in 2001, this meeting has grown to nearly 600 attendees and has become the premier forum for discussion on the latest advances in myeloproliferative diseases and myelodysplastic syndromes. It allows attendees a forum to update their knowledge in the field, confirm their current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.

Guided by the expertise of the leaders in the fi elds of molecular biology, pathology, immunology, and translational and clinical research, this Congress promises to be a stimulating, interactive forum for attendees from all relevant medical specialties. We will focus on the most recent updates and debates centered around polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia and myelodysplasia.

With its diverse mix of oncologists, hematologists, surgeons, and pathologists, this will be a great place to interact with your colleagues and learn from internationally renowned faculty.

We look forward to welcoming you in November to New York as the Fall brings its special beauty to this exciting international city!

Richard T. Silver, MD, FACP
Chair and Convener

Jerry L. Spivak, MD, FACP



11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

PDF Announcement

PDF Announcement

Endorsing Societies:
MDS Foundation


The following companies have provided an educational grant in support of this Congress:





Bristol-Myers Squibb




Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

The following companies are exhibitors at this congress:



Glaxo Smith Kline Oncology





Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.